Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | EPOR | P19235 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16965479 | 1.00 | TDP1 (0.56) | TDP1ATMACHETP53MAPT | |
| SCHEMBL16964684 | 0.89 | TDP1 (0.57) | TDP1ATMACHETP53MAPT | |
| SCHEMBL24742779 | 0.81 | ALDH1A1 (0.47) | TDP1TP53MAPTKMT2AALDH1A1 | |
| SCHEMBL5161216 | 0.78 | KMT2A (0.43) | TDP1ATMTP53MAPTKMT2A | |
| SCHEMBL5161221 | 0.78 | KMT2A (0.43) | TDP1ATMTP53MAPTKMT2A | |
| SCHEMBL26618376 | 0.78 | ALDH1A1 (0.49) | TDP1ACHEKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL26618380 | 0.78 | ALDH1A1 (0.49) | TDP1ACHEKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16964741 | 0.76 | TDP1 (0.48) | TDP1ACHEMAPTCASRTAS2R14 | |
| SCHEMBL23494950 | 0.75 | ESR1 (0.63) | TDP1ATMCASRKMT2AALDH1A1 | |
| SCHEMBL25294876 | 0.75 | TDP1 (0.60) | TDP1ATMACHETAS2R14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900241-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2900223-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9233979-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9226922-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| EP-2900241-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900223-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | TDP1 2597/4885ATM 585/4885ACHE 4359/4885 |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | TDP1 867/4885ATM 468/4885ACHE 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.